Published in BMC Med on March 02, 2012
Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol (2015) 1.43
Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes. Anticancer Res (2012) 1.18
Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res (2014) 0.97
Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget (2015) 0.92
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer (2014) 0.88
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res (2014) 0.87
Loss of AMPKα1 expression is associated with poor survival in melanoma patients. J Invest Dermatol (2014) 0.86
Identification of a novel family of BRAF(V600E) inhibitors. J Med Chem (2012) 0.85
RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells. Epigenetics (2014) 0.84
Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ (2015) 0.84
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res (2013) 0.84
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis (2013) 0.84
Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol (2014) 0.83
Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther (2014) 0.82
Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. BMC Cancer (2016) 0.81
Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther (2014) 0.81
HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis. J Cell Mol Med (2014) 0.81
Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. PLoS One (2013) 0.79
Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor. J Surg Res (2014) 0.79
Synthesis and Biological Evaluation of New Quinoxaline Derivatives of ICF01012 as Melanoma-Targeting Probes. ACS Med Chem Lett (2014) 0.78
Enhancement of electroporation facilitated immunogene therapy via T-reg depletion. Cancer Gene Ther (2014) 0.78
Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin. Oncotarget (2016) 0.78
MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility. Oncotarget (2015) 0.78
MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A (2015) 0.77
Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. PLoS One (2012) 0.76
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget (2016) 0.76
Intravital fluorescence imaging of small interfering RNA-mediated gene repression in a dual reporter melanoma xenograft model. Nucleic Acid Ther (2012) 0.76
Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas. PLoS One (2016) 0.75
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol (2017) 0.75
Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget (2016) 0.75
Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. Neoplasia (2016) 0.75
Immunotherapy in the management of melanoma: current status. Immunotargets Ther (2013) 0.75
High intensity focused ultrasound inhibits melanoma cell migration and metastasis through attenuating microRNA-21-mediated PTEN suppression. Oncotarget (2016) 0.75
Notch ligand Delta-like 1 promotes the metastasis of melanoma by enhancing tumor adhesion. Braz J Med Biol Res (2014) 0.75
Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant (2012) 0.75
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight (2017) 0.75
Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma. Invest New Drugs (2014) 0.75
Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biol (2017) 0.75
Indomethacin to the rescue of TRAIL-resistant melanomas. J Invest Dermatol (2014) 0.75
Triptolide-Mediated Apoptosis by Suppression of Focal Adhesion Kinase through Extrinsic and Intrinsic Pathways in Human Melanoma Cells. Evid Based Complement Alternat Med (2013) 0.75
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells. Drug Des Devel Ther (2016) 0.75
The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. Lasers Med Sci (2017) 0.75
Effects of ursolic and oleanolic on SK‑MEL‑2 melanoma cells: In vitro and in vivo assays. Int J Oncol (2017) 0.75
A quantitative method for screening and identifying molecular targets for nanomedicine. J Control Release (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 21.13
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 4.95
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70
PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer (2000) 1.61
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res (2009) 1.56
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol (2001) 1.55
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47
Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer (2008) 1.43
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol (2004) 1.35
The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology (2008) 1.29
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res (2011) 1.28
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays (2007) 1.26
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer (2011) 1.21
Surgical therapy for distant metastases of malignant melanoma. Cancer (2000) 1.20
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci (2009) 1.15
Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg (2001) 1.14
The surgical management of metastatic melanoma. Ann Surg Oncol (2002) 1.03
Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech (2003) 1.02
Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia (2011) 0.96
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res (2011) 0.93
Adoptive cell therapy for patients with melanoma. J Cancer (2011) 0.86
Selected patients with metastatic melanoma may benefit from liver resection. World J Surg (2007) 0.83
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
In-transit melanoma: an individualized approach. Oncology (Williston Park) (2011) 2.24
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma (2012) 1.72
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica (2011) 1.60
Age-period-cohort analysis of renal cell carcinoma in United States adults. Urology (2013) 1.54
Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol (2010) 1.46
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant (2008) 1.37
Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol (2006) 1.36
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 1.34
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer (2006) 1.27
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 1.25
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol (2011) 1.24
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
Vemurafenib for melanoma metastases to the brain. N Engl J Med (2011) 1.21
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol (2008) 1.17
Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol (2002) 1.16
CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med (2009) 1.15
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol (2009) 1.14
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 1.14
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol (2010) 1.05
Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol (2004) 1.03
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.02
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys (2013) 1.02
Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc (2012) 1.00
Clopidogrel-associated autoimmune thrombocytopenic purpura. Catheter Cardiovasc Interv (2004) 1.00
Chylothorax in chronic lymphocytic leukemia patient. Am J Hematol (2002) 1.00
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol (2007) 0.98
Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. J Vasc Interv Radiol (2012) 0.97
Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res (2010) 0.97
Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc (2004) 0.97
Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol (2010) 0.97
Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 0.97
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol (2012) 0.97
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Cancer (2007) 0.96
Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Am J Clin Oncol (2014) 0.95
Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol (2003) 0.95
Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 0.95
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood (2011) 0.95
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer (2010) 0.95
The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res (2016) 0.94
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res (2005) 0.94
A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer (2007) 0.94
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma (2014) 0.93
Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol (2014) 0.92
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol (2014) 0.91
Treatment of brain metastases from melanoma. Mayo Clin Proc (2003) 0.90
Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res (2011) 0.88
Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. Respir Med (2006) 0.88
Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma (2003) 0.88
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol (2011) 0.86
Emerging therapies for melanoma. Expert Rev Anticancer Ther (2008) 0.86
Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) (2012) 0.86
Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res (2011) 0.86
Regional lymphatic immunity in melanoma. Melanoma Res (2012) 0.86
Novel therapeutics for the treatment of metastatic melanoma. Future Oncol (2009) 0.86
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res (2013) 0.86
Pediatric melanoma: analysis of an international registry. Cancer (2013) 0.86
New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant (2009) 0.86
The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol (2015) 0.85
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol (2013) 0.85
Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma. Carcinogenesis (2013) 0.85
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology (2013) 0.85
Changing surgical therapy for melanoma of the external ear. Ann Surg Oncol (2003) 0.84
Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. Cancer Immunol Res (2013) 0.84
Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psychooncology (2012) 0.84
An integrated model of the transcriptome of HER2-positive breast cancer. PLoS One (2013) 0.84
The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma Res (2015) 0.84
Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period. Am J Reprod Immunol (2014) 0.83
The dynamic human immune response to cancer: it might just be rocket science. Immunotherapy (2011) 0.82
Metastatic malignant melanoma manifesting as an intracardiac mass. Cardiovasc Pathol (2009) 0.81
c-MET expression in primary and liver metastases in uveal melanoma. Melanoma Res (2014) 0.81
Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma. Mayo Clin Proc (2011) 0.81
Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res (2017) 0.80
Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res (2015) 0.80
Molecular targets in melanoma: time for 'ethnic personalization'. Expert Rev Anticancer Ther (2012) 0.80
Malignant basomelanocytic tumor manifesting as metastatic melanoma. Am J Surg Pathol (2004) 0.80
Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin Dev Immunol (2010) 0.80
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma (2006) 0.80
mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD). Am J Hematol (2008) 0.80
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma (2007) 0.79
AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma (2007) 0.79
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leuk Lymphoma (2005) 0.79
Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma. Cancer (2013) 0.78
Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol (2010) 0.77